Table of Contents Author Guidelines Submit a Manuscript
ISRN Rheumatology
Volume 2013 (2013), Article ID 215034, 6 pages
Review Article

Oral Bisphosphonate Related Osteonecrosis of the Jaw: A Challenging Adverse Effect

Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Cukurova University, Adana 01330, Turkey

Received 8 April 2013; Accepted 1 May 2013

Academic Editors: P. Voulgari and L. Xing

Copyright © 2013 Ilke Coskun Benlidayi and Rengin Guzel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Oral bisphosphonates are the most commonly prescribed antiresorptive drugs for the treatment of osteoporosis. However, there are several adverse effects associated with oral bisphosphonates including the bisphosphonate related osteonecrosis of the jaw (BRONJ). With a better understanding of this side effect, reported incidences for BRONJ in oral bisphosphonate users have increased in time. The pathogenesis of BRONJ has not been well determined. Several risk factors such as dentoalveolar surgery, therapy duration, and concomitant steroid usage have been linked to BRONJ. Conservative and surgical methods can be preferred in the treatment. Preventative measures are of great importance for the patients at high risk. In this paper, osteonecrosis of the jaw secondary to oral bisphosphonates was reviewed in order to increase awareness as well as to renew the current knowledge.